

8.2 cm

2.0 - May 2025

Subcutaneous use only

3.5mg Powder

3.5mg Reconstitution volume

2.5 mg/ml Final concentration

Route of administration

Reconstitution of Bortezomib solution for SC injection

Subcutaneous use only

3.5mg Powder

3.5mg Reconstitution volume

1.0 mg/ml Final concentration

Route of administration

Reconstitution of Bortezomib solution for IV injection

From the formula of Dubois and Dubois, Arch Intern Med 1916;17:863

Bortezomib must be reconstituted by a Health Care Professional. Each vial of Bortezomib must be carefully reconstituted by using a syringe of the appropriate size without removing the vial top. Aseptic technique must be strictly observed throughout the handling of Bortezomib since no preservative is present.

Height (cm)

Weight (kg)

Height (in)

Body Surface Area (m²)

TRANSSPARENT

Borvix[®] (Bortezomib)

3.5mg powder for solution for injection

2.0 - May 2025

Method of administration

IV administration:

The reconstituted solution is administered as a 3-5 second bolus intravenous injection through a peripheral or central intravenous catheter followed by a flush with sodium chloride 9 mg/ml (0.9%) solution for injection.

SC administration:

The reconstituted solution is administered subcutaneously in the thighs (right or left, proximal and distal sites) or abdomen (right or left, upper or lower quadrant). Injection sites should be rotated for successive injections.

References:
1. Borvix[®] (Bortezomib) 3.5mg powder for solution for injection leaflet and SmPC
2. Bortezomib leaflet(2019). Retrieved 9 July 2020, from https://www.velcade.com/files/pdfs/VELCADE_PRESCRIBING_INFORMATION.pdf
3. Dosing Slide Rule - Bortezomib 2.5mg/ml Solution for Injection (3.5mg total content). Retrieved 9 July 2020, from <https://www.medicines.org.uk/emc/mmv/1426/Document>

Borvix[®] (Bortezomib)

3.5mg powder for solution for injection

After determining patient body surface area (BSA) in square meters, use the following equations to calculate the total volume (mL) of reconstituted Borvix[®] to be administered:

- Intravenous Administration [1 mg/mL concentration]:

$$\frac{\text{Borvix}^{\text{®}} \text{ dose (mg/m}^2\text{) x patient BSA (m}^2\text{)}}{1\text{mg/ml}} = \text{Total Borvix volume (ml) to be administered}$$

- Subcutaneous Administration [2.5 mg/mL concentration]

$$\frac{\text{Borvix}^{\text{®}} \text{ dose (mg/m}^2\text{) x patient BSA (m}^2\text{)}}{2.5\text{mg/ml}} = \text{Total Borvix volume (ml) to be administered}$$

Example	Body Surface (m ²)	Total dose required (in mg) with 1.3mg/m ²	Applied volume with IV use (in mL)	Applied volume with SC use (in mL)
	1.5	1.95	1.95	0.78
	1.6	2.08	2.08	0.83
	1.7	2.21	2.21	0.88
	1.8	2.34	2.34	0.94
	1.9	2.47	2.47	0.99
	2.0	2.60	2.60	1.04
	2.1	2.73	2.73	1.09

mspharma

INSTRUCTIONS:

Pull out and match patient weight with patient height. Read Body Surface Area at arrow. Please see Precautions and Posology and Method of Administration sections of SmPC for dose modification information.

Call For Reporting:

Pharmacovigilance department at MS Pharma:
Email: pharmacovigilance@mspharma.com
Website: www.mspharma.com
Phone No: + 9661 12790122 Ext. 6013
The National Pharmacovigilance Center (NPC):
(Saudi food and drug authority)
Email: npc.drug@sda.gov.sa
Call Center: 19999
Website: <https://ada.sda.gov.sa/>
QR Code:

This document is approved by The Executive Directorate of Pharmacovigilance, at SFDA

18.4cm

21.6cm

21.6cm

8.1 cm

